检索结果-南通市图书馆

SYNBIOcHEM Synthetic Biology Research centre, Manchester-A UK foundry for fine and speciality chemicals production

Synthetic and Systems Biotechnology 2016年第4期1卷 271-275页

作者： Le Feuvre RA carbonell P currin A Dunstan M Fellows D Jervis AJ Rattray NJW Robinson cJ Swainston N vinaixa M Williams A Yan c Barran P Breitling R chen GG Faulon JL Goble c Goodacre R Kell DB Micklefield J Scrutton NS Shapira P Takano E Turner NJ Manchester centre for Synthetic Biology of Fine and Speciality chemicals(SYNBIOcHEM) Manchester Institute of BiotechnologyFaculty of Life SciencesUniversity of ManchesterOxford RoadManchesterM139PTUnited Kingdom SYNBIOcHEM Data LeadSchool of Computer ScienceThe University of ManchesterManchesterM139PTUnited Kingdom SYNBIOcHEM Responsible Research and Innovation LeadAlliance Manchester Business SchoolUniversity of ManchesterManchesterM139PTUnited Kingdom

The UK Synthetic Biology Research centre,SYNBIOcHEM,hosted by the Manchester Institute of Biotechnology at the University of Manchester is delivering innovative technology platforms to facilitate the predictable engineering of microbial bio-factories for fine and speciality chemicals *** provide an overview of our foundry activities that are being applied to grand challenge projects to deliver innovation in bio-based chemicals production for industrial biotechnology.

关键词： Synthetic chemicals Manchester

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Liver fat deposition and mitochondrial dysfunction in morbid obesity:An approach combining metabolomics with liver imaging and histology

引用

World Journal of Gastroenterology 2015年第24期21卷 7529-7544页

作者： Nahum calvo Raúl Beltrán-Debón Esther Rodríguez-Gallego Anna Hernández-Aguilera Maria Guirro Roger Mariné-casadó Lidón Millá Josep M Alegret Fàtima Sabench Daniel del castillo María vinaixa Miguelàngel Rodríguez Xavier correig Roberto García-álvarez Javier A Menendez Jordi camps Jorge Joven Unitat de Recerca Biomèdica Hospital Universitari de Sant JoanInstitut d’Investigacio Sanitària Pere VirgiliUniversitat Rovira i VirgiliCampus of International Excellence Southern Catalonia Servei de cirurgia General i de l’Aparell Digestiu Hospital Universitari de Sant Joan de ReusUniversitat Rovira i Virgili Metabolomics Platform Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas AsociadasIISPVUniversitat Rovira i Virgili Research and collaborations General Electric Healthcare Metabolism and cancer Group Transla-tional Research LaboratoryCatalan Institute of OncologyGirona Biomedical Research Institute

AIM: To explore the usefulness of magnetic resonance imaging(MRI) and spectroscopy(MRS) for assessment of non-alcoholic fat liver disease(NAFLD) as compared with liver histological and metabolomics findings. METHODS: Patients undergoing bariatric surgery following procedures involved in laparoscopic sleeve gastrectomy were recruited as a model of obesityinduced NAFLD in an observational, prospective, singlesite, cross-sectional study with a pre-set duration of 1 year. Relevant data were obtained prospectively and surrogates for inflammation, oxidative stress and lipid and glucose metabolism were obtained through standard laboratory measurements. To provide reliable data from MRI and MRS, novel procedures were designed to limit sampling variability and other sources of error using a 1.5T Signa HDx scanner and protocols acquired from the 3D or 2D Fat SAT FIESTA prescription manager. We used our previously described 1H NMRbased metabolomics assays. Data were obtained immediately before surgery and after a 12-mo period including histology of the liver and measurement of metabolites. Values from 1H NMR spectra obtained after surgery were omitted due to technical ***: MRI data showed excellent correlation with the concentration of liver triglycerides, other hepatic lipid components and the histological assessment, w h i c h e xc l u d e d t h e p r e s e n c e o f n o n-a l c o h o l i c steatohepatitis(NASH). MRI was sufficient to follow up NAFLD in obese patients undergoing bariatric surgery and data suggest usefulness in other clinical situations. The information provided by MRS replicated that obtained by MRI using the-cH3 peak(0.9 ppm), the-cH2- peak(1.3 ppm, mostly triglyceride) and the-cH=cH- peak(2.2 ppm). No patient depicted NASH. After surgery all patients significantly decreased their body weight and steatosis was virtually absent even in patients with previous severe disease. Improvement was also observed in the serum concentrations of selected

关键词： Fatty liver disease Magnetic resonanceimaging Lipids Magnetic resonance spectroscopy Metabolomics Mitochondrial function Morbid obesity Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Predictive factors for survival and score application in liver retransplantation for hepatitis c recurrence

引用

World Journal of Gastroenterology 2016年第18期22卷 4547-4558页

作者： Alice Tung Wan Song Rodolphe Sobesky c.rmen vinaixa Jérome Dumortier Sylvie Radenne Francois Durand Yvon calmus Géraldine Rousseau Marianne Latournerie cyrille Feray Valérie Delvart Bruno Roche Stéphanie Haim-Boukobza Anne-Marie Roque-Afonso Denis castaing Edson Abdala Luiz Augusto carneiro D’Albuquerque Jean-charles Duclos-Vallée Marina Berenguer Didier Samuel INSERM Unit 785 Villejuif 94800France Liver and Digestive Organ Transplantation Division Gastroenterology DepartmentUniversity of Sao Paulo Medical SchoolSao Paulo 05403-900Brazil Universite Paris-Sud Villejuif 94800France Liver Transplantation Laboratory LIM-37 Sao Paulo 01246-903Brazil AP-HP Hopital Paul Brousse Villejuif 94800France La Fe Hospital University of Valencia and CiberehdValencia 46026Spain Hopital Edouard Herriot Lyon 69003France Hopital croix Rousse Lyon 69004France AP-HP Hopital Beaujon Clichy 92110France AP-HP Hopital St Antoine Paris 75011France AP-HP Hopital Salpetriere Paris 75013France cHU Pontchaillou Rennes 35000France AP-HP Hopital Henri Mondor Creteil 94010France Viral Hepatitis Laboratory LIM-47 Sao Paulo 01246-903Brazil

AIM: To identify risk factors associated with survival in patients retransplanted for hepatitis c virus(HcV) recurrence and to apply a survival score to this ***: We retrospectively identified 108 patients retransplanted for HcV recurrence in eight European liver transplantation centers(seven in France, one in Spain). Data collection comprised clinical and laboratory variables, including virological and antiviral treatment data. We then analyzed the factors associated with survival in this population. A recently published score that predicts survival in retransplantation in patients with hepatitis c was applied. Because there are currently no uniform recommendations regarding selection of the best candidates for retransplantation in this setting, we also described the clinical characteristics of 164 patients not retransplanted, with F3, F4, or fibrosing cholestatic hepatitis(FcH) post-first graft presenting with hepatic decompensation. RESULTS: Overall retransplantation patient survival rates were 55%, 47%, and 43% at 3, 5, and 10 years, respectively. Patients who were retransplanted for advanced cirrhosis had survival rates of 59%, 52%, and 49% at 3, 5, and 10 years, while those retransplanted for FcH had survival rates of 34%, 29%, and 11%, respectively. Under multivariate analysis, and adjusting for the center effect and the occurrence of FcH, factors associated with better survival after retransplantation were: negative HcV viremia before retransplantation, antiviral therapy after retransplantation, non-genotype 1, a Model for End-stage Liver Disease(MELD) score ced on the waiting list, and a retransplantation donor age context of the new antivirals era, we showed that outcomes in patientswho underwent retransplantation with undetectable HcV viremia did not depend on donor age and MELD score. The Andrés score was applied to 102 patients for whom all score variables were available,

关键词： Antivirals Hepatitis c Mortality Prognosis Retransplantation Risk factors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effectiveness and safety of first-generation protease inhibitors in clinical practice:Hepatitis c virus patients with advanced fibrosis

引用

World Journal of Gastroenterology 2015年第30期21卷 9163-9174页

作者： Javier Salmeron c.rmen vinaixa Ruben Berenguer Juan Manuel Pascasio Juan Jose Sanchez Ruano Miguel angel Serra Ana Gila Moises Diago Manuel Romero-Gomez Jose Maria Navarro Milagros Testillano conrado Fernandez Dolores Espinosa Isabel carmona Jose Antonio Pons Francisco Jorquera Francisco Javier Rodriguez Ramon Perez Jose Luis Montero Rafael Granados Miguel Fernandez Ana Belen Martin Paloma Munoz de Rueda Rosa Quiles cIBERehd Instituto de Salud Carlos Ⅲ28029 MadridSpain Unit for clinical Management of Digestive Diseases Complejo Hospitalario Universitario de Granada Instituto de Investigacion Biosanitaria de Granada University Hospital Politecnico La Fe Unit for clinical Management of Digestive Diseases University Hospital Virgen Del Rocio Hospital Toledo University clinic Hospital of Valencia University General Hospital of Valencia Unit for clinical Management of Digestive Diseases University Hospital Nuestra Senora de Valme Department of Gastroenterology and Hepatology Agencia Sanitaria costa del Sol University Hospital cruces Gastroenterology Unit University Hospital Fundacion Alcorcon University Hospital Virgen Macarena University Hospital Virgen de la Arrixaca Hospital of Leon University General Hospital Reina Sofia Department Gastroenterology and Hepatology University Hospital Central de Asturias University Hospital Reina Sofia University Hospital De Gran canaria Dr. Negrin Hospital San Pedro de Alcantara

AIM:To evaluates the effectiveness and safety of the first generation,NS3/4A protease inhibitors(PIs) in clinical practice against chronic c virus,especially in patients with advanced fibrosis. METHODS:Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis c genotype 1,treatment-na?ve(TN) or treatment-experienced(TE),who underwent triple therapy with the first generation NS3/4A protease inhibitors,boceprevir(BOc) and telaprevir(TVR),in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow ***:One thousand and fifty seven patients were included,405(38%) were treated with BOc and 652(62%) with TVR. Of this total,30%(n = 319) were TN and the remaining were TE:28%(n = 298) relapsers,12%(n = 123) partial responders(PR),25%(n = 260) null-responders(NR) and for 5%(n = 57) with prior response unknown. The rate of sustained virologic response(SVR) by intention-to-treatment(ITT) was greater in those treated with TVR(65%) than in those treated with BOc(52%)(P cant differences. By degree of fibrosis,56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients,both TN and TE. In the analysis by groups,the TN patients treated with TVR by ITT showed a higher SVR(P = 0.005). However,by m ITT there were no significant differences between BOc and TVR. In the multivariate analysis by m ITT,the significant SVR factors were relapsers,IL28 B cc and non-F4; the type of treatment(BOc or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients,treated with BOc(46%) or with TVR(45%). 28% of the patients interrupted the treatment,mainly by non-viral response(51%):this outcome was

关键词： Hepatitis c Boceprevir Telaprevir First-generation protease inhibitors Advanced fibrosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：